Form 8-K - Current report:
SEC Accession No. 0001193125-24-251712
Filing Date
2024-11-06
Accepted
2024-11-06 08:01:53
Documents
14
Period of Report
2024-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d910412d8k.htm   iXBRL 8-K 24959
2 EX-99.1 d910412dex991.htm EX-99.1 75955
  Complete submission text file 0001193125-24-251712.txt   238121

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA urgn-20241106.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE urgn-20241106_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE urgn-20241106_pre.xml EX-101.PRE 11259
16 EXTRACTED XBRL INSTANCE DOCUMENT d910412d8k_htm.xml XML 3644
Mailing Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007
Business Address 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
UroGen Pharma Ltd. (Filer) CIK: 0001668243 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38079 | Film No.: 241429295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)